HMG Biologics is the Italian operating company of KCFB S.A., a privately owned biotechnology company established in 2019 on the basis of a long and proven experience of the founding partners in the biotech sector . KCFB operates in the field of regenerative medicine with the aim of creating and delivering innovative clinical treatments through the development of Advanced Therapy Medicinal Products (ATMPs), falling under EU Regulation 1394/2007.
Our products are based on a proprietary, patented technology platform for the use of human cells as biocarriers of alarmins, endogenous molecules that are constitutively available and released through the company’s proprietary industrial process. Alarmins restore the normal wound’s micro environment: no available products currently have such cure potential.
FBPlus is our first ATMP product, a novel allogeneic epidermal and dermal substitute for the treatment of chronic lower limb ulcers (CLLU). It characterized by its contents in HMGB1 group proteins, as markers of its role as biocarrier of alarmines capable of promoting tissue regeneration and repair. It is classified as a Tissue Engineering Product by the EMA.
FBPlus is able to restore the normal microenvironment of chronic wounds activating the healing process in a very efficient way. As of now, we are not aware of any products with this same mechanism of action and comparable efficacy